JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-07-06 pm EDT
178.30 USD   +0.09%
07/01DOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules
DJ
07/01Pharmaceutical companies still have the upper hand
06/30Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Main events scheduled for Monday, May 30

05/28/2022 | 11:38pm EDT

Main events scheduled in Japan for Monday, May 30:

-- Health ministry panel to discuss whether to approve coronavirus vaccine developed by U.S. pharmaceutical company Johnson & Johnson.

-- Nagasaki District Court to hand down ruling at 10 a.m. over 2007 alleged sexual assault against female reporter by now-deceased Nagasaki city official.

==Kyodo

© Kyodo News International, Inc., source Newswire

All news about JOHNSON & JOHNSON
07/01DOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules
DJ
07/01Pharmaceutical companies still have the upper hand
06/30Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for..
AQ
06/30Hywin Holdings, FactSet Launch Global Health Care Index
MT
06/29NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
AQ
06/29Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i..
MT
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
MT
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 505 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,8x
Yield 2022 2,50%
Capitalization 469 B 469 B -
EV / Sales 2022 4,77x
EV / Sales 2023 4,49x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 178,30 $
Average target price 187,28 $
Spread / Average Target 5,04%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.13%469 179
ELI LILLY AND COMPANY18.45%297 188
PFIZER, INC.-12.55%295 975
ROCHE HOLDING AG-14.71%272 233
ABBVIE INC.12.65%269 537
NOVO NORDISK A/S9.97%250 712